135 related articles for article (PubMed ID: 37731146)
1. The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.
Candan O; Demirtas D; Yanik AM; Atagunduz I; Toptas T
Ann Hematol; 2023 Dec; 102(12):3647-3648. PubMed ID: 37731146
[No Abstract] [Full Text] [Related]
2. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
3. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of ruxolitinib and ponatinib in patients with
Niswander LM; Loftus JP; Lainey É; Caye-Eude A; Pondrom M; Hottman DA; Iacobucci I; Mullighan CG; Jain N; Konopleva M; Cavé H; Baruchel A; Rohrlich PS; Tasian SK
Haematologica; 2021 Oct; 106(10):2763-2767. PubMed ID: 34196168
[No Abstract] [Full Text] [Related]
7. Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.
Bayram N; Yaman Y; Özdilli K; Telhan L; Nepesov S; Bilgen H; Elli M; Behar SS; Anak S
Pediatr Transplant; 2021 Jun; 25(4):e14024. PubMed ID: 33860589
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
9. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract][Full Text] [Related]
10. BCL6 inhibition ameliorates resistance to ruxolitinib in
Tsuzuki S; Yasuda T; Goto H; Maeda N; Akahane K; Inukai T; Yamamoto H; Karnan S; Ota A; Hyodo T; Konishi H; Hosokawa Y; Kiyoi H; Hayakawa F
Haematologica; 2023 Feb; 108(2):394-408. PubMed ID: 36005560
[TBL] [Abstract][Full Text] [Related]
11. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Wells J; Jain N; Konopleva M
Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
[TBL] [Abstract][Full Text] [Related]
12. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
13. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
14. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
15. A potential role of ruxolitinib in leukemia.
Naqvi K; Verstovsek S; Kantarjian H; Ravandi F
Expert Opin Investig Drugs; 2011 Aug; 20(8):1159-66. PubMed ID: 21635221
[TBL] [Abstract][Full Text] [Related]
16. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
[No Abstract] [Full Text] [Related]
17. Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
Ostergaard J; Jonart LM; Ebadi M; Koppenhafer SL; Gordon DJ; Gordon PM
Br J Haematol; 2021 Sep; 194(6):1094-1098. PubMed ID: 34096630
[TBL] [Abstract][Full Text] [Related]
18. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Walker KL; Rinella SP; Hess NJ; Turicek DP; Kabakov SA; Zhu F; Bouchlaka MN; Olson SL; Cho MM; Quamine AE; Feils AS; Gavcovich TB; Rui L; Capitini CM
Leuk Lymphoma; 2021 May; 62(5):1167-1177. PubMed ID: 33843403
[TBL] [Abstract][Full Text] [Related]
20. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
